Anti-angiogenic drugs can facilitate the infiltration and activation of immune cells within tumours, mediate the upregulation of IFNγ, enhance the expression of PD-1 and PD-L1, boost the sensitivity of immunotherapy within tumours, alter the M1/M2 ratio of tumour-associated macrophages, diminish the infiltration of regulatory T cells and monocytes in tissues, restructure the tumour immune microenvironment, and effectively elevate the efficacy of immunotherapy [11, 12]. Here, IFNG is linked to neoplasm.